Vepdegestrant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Vepdegestrant. Educational only — not medical advice.
Labeled uses
VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Source: FDA labeling via NIH DailyMed (set 751e18d5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.